Gabapentin Tablet, Film Coated
Product Images NDC 71335-1601

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1601). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration showing the formula to calculate creatinine clearance (CLCr), which includes age, weight, serum creatinine, and a factor for female patients (0.85). This calculation is used to estimate kidney function.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of gabapentin showing a cyclohexane ring attached to an aminomethyl group and an acetic acid side chain.*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph comparing mean pain scores over eight weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. The graph indicates a decreasing pain trend in the Gabapentin group, while placebo scores remain relatively stable.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain scores over a 7-week period comparing placebo and two gabapentin doses, 1800 mg/day and 2400 mg/day, during a 3-week dose titration period followed by a 4-week fixed dose period. The Y-axis represents mean pain scores, and the X-axis shows weeks from baseline to week 7.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing response rates across two studies. The vertical axis shows percentage from 0% to 100%. Study 1 compares placebo (12%) and Gabapentin 3600 mg (29%). Study 2 compares placebo (14%), Gabapentin 1800 mg (32%), and Gabapentin 2400 mg (34%). Statistical significance is indicated with p-values (p < 0.01 and p < 0.001).*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot showing the difference percentage on the y-axis versus daily dose in mg on the x-axis for Gabapentin. Data points represent three studies labeled as Study a, Study b, and Study c, with doses ranging from 600 mg to 1800 mg and corresponding difference percentages from about 7% to 17%.*

FDA Label Image

Label Image (Lbl713351601)

Gabapentin 800 mg film-coated tablet label by Bryant Ranch Prepack. The label states it is comparable to Neurontin 800 mg tablets and provides storage instructions at 20°-25°C (68°-77°F). It includes warnings about dizziness and keeping drugs out of reach of children. The package contains 30 tablets and displays both the NDC 71335-1601-1 and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.